Page 267 - Tata_Chemicals_yearly-reports-2020-2021

Integrated Report Statutory Reports Financial Statements
1-59 60-146 Consolidated

(ii) Deferred tax liabilities (net) ` in crore
Recognised in Recognised in Recognised
As at Ind-AS 116 As at
profit or loss
Exchange
in other
April 1, profit or loss (discontinued comprehensive Transition Others fluctuations March 31,
(continuing
2020 Impact 2021
operations) operations) income
Deferred tax assets/(liabilities) in
relation to:
Property, plant and equipments (PPE)
and intangible asset (1,410.43) 16.74 - - - - 39.04 (1,354.65)
Acquisition of non-controlling interest
(PPE and Intangible) (168.43) (19.69) - - - - 5.98 (182.14)
Allowance for doubtful debts and
Advances 35.64 1.33 - - - - - 36.97
Accrued expenses allowed in the
year of payment and on fair value of
investments 86.66 12.25 - (142.01) - - - (43.10)
Mark to market gains on mutual funds
and derivatives (24.46) (0.84) - - - - - (25.30)
Right-of-use assets and lease liability 11.11 (1.46) - - - - - 9.65
Financial assets at FVTOCI 5.64 (0.39) - - - - (0.04) 5.21
Partnership tax basis differences for
USA Subsidiaries (16.84) 3.26 - (48.29) - - 1.24 (60.63)
Defined benefit obligation 45.96 2.44 - (33.47) - - (1.05) 13.88
Others (including other payables) (2.79) 29.70 - (0.68) - - 1.77 28.00
(1,437.94) 43.34 - (224.45) - - 46.94 (1,572.11)

` in crore
Recognised in
Recognised in Recognised
As at profit or loss Ind-AS 116 As at
April 1, profit or loss (discontinued in other Transition Others** Exchange March 31,
2019 (continuing operations) comprehensive Impact fluctuations 2020
operations) income
(note 36)
Deferred tax assets/(liabilities) in
relation to:
Property, plant and equipments (PPE)
and intangible asset (1,390.22) 93.94 - - - (13.37) (100.78) (1,410.43)
Acquisition of non-controlling interest
(PPE and Intangible) - (1.47) - - - (156.30) (10.66) (168.43)
Allowance for doubtful debts and
Advances 51.54 (16.26) - - - 0.36 - 35.64
Accrued expenses allowed in the
year of payment and on fair value of
investments 28.41 (13.94) 6.77 65.42 - - - 86.66
Mark to market gains on mutual funds
and derivatives (19.94) (4.52) - - - - - (24.46)
Right-of-use assets and lease liability - 9.10 - - 1.84 0.17 - 11.11
Financial assets at FVTOCI 5.53 - - - - - 0.11 5.64
Partnership tax basis differences for
USA Subsidiaries (38.17) 4.53 - 18.82 - - (2.02) (16.84)
Defined benefit obligation 30.86 (1.84) - 14.77 - (1.32) 3.49 45.96
Alternative Minimum Tax ('AMT') Credit 64.09 (18.19) - - - (47.50) 1.60 -
Others (including other payables) (29.28) (4.46) 31.86 0.98 - 1.66 (3.55) (2.79)
(1,297.18) 46.89 38.63 99.99 1.84 (216.30) (111.81) (1,437.94)
**Includes Impact of Tax Receivables (on AMT), transfer to discontinued operation, Impact of Merger of Metahelix Life Sciences Limited
with Rallis India Limited and Impact due to acquisition of non-controlling interest on PPE and Intangible assets.

265